Coherus Oncology (CHRS) Current Assets (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Current Assets data on file, last reported at $206.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 33.57% year-over-year to $206.0 million; the trailing twelve-month figure through Mar 2026 stood at $206.0 million (down 33.57% YoY), and the FY2025 full-year result was $206.7 million, down 39.49% from the prior year.
• Current Assets steadied at $206.0 million in Q1 2026, from $206.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $627.5 million in Q1 2024 to a low of $206.0 million in Q1 2026.
• A 5-year average of $404.1 million and a median of $385.5 million in 2023 frame the typical range for Current Assets.
• Across the five-year window, Current Assets jumped 98.62% in 2024 and slumped 50.57% in 2025, its largest moves.
• Tracing CHRS's Current Assets over 5 years: stood at $381.2 million in 2022, then gained by 24.76% to $475.6 million in 2023, then slipped by 28.18% to $341.6 million in 2024, then tumbled by 39.49% to $206.7 million in 2025, then retreated by 0.32% to $206.0 million in 2026.
• Business Quant data shows CHRS's Current Assets at $206.0 million in Q1 2026, $206.7 million in Q4 2025, and $461.0 million in Q3 2025.